Allison R Bechard1, Lori A Knackstedt2. 1. Department of Psychology, University of Florida, Gainesville, FL, 32603, USA. 2. Department of Psychology, University of Florida, Gainesville, FL, 32603, USA. Electronic address: knack@ufl.edu.
Abstract
BACKGROUND: Cocaine use disorder is a significant public health problem and currently no medications are FDA-approved to reduce cocaine relapse. Drug-associated cues are reported to elicit craving and cocaine-seeking in humans. Repeated, non-reinforced presentations of drug-associated cues (cue extinction) have been proposed to reduce the ability of such cues to prompt drug-seeking. In rodent models of cocaine relapse, cue extinction reduces cocaine relapse when such extinction occurs in the same context as cocaine self-administration, which is not akin to the manner in which treatment would occur in humans. Here we sought to determine whether cue extinction outside of the cocaine self-administration context would reduce relapse in the drug context. We also hypothesized that ceftriaxone, an antibiotic consistently shown to attenuate cocaine relapse in rats, would enhance the relapse-preventing effects of cue extinction. METHODS: Rats self-administered intravenous cocaine for 12 days followed by 20-21 days of abstinence. Immediately preceding the relapse test, rats either underwent 6 single daily cue extinction sessions (1 h/day) outside the self-administration context or no extinction with daily handling. Rats also received vehicle or ceftriaxone (200 mg/kg IP) on those six days. RESULTS: Ceftriaxone attenuated cued relapse relative to vehicle-treated rats, but there was no additive effect of cue extinction on cocaine-seeking. Cue extinction alone did not attenuate relapse. CONCLUSIONS: Thus, in agreement with work in humans, when cue extinction is conducted outside the drug-associated context it does not reduce the risk of relapse alone. Ceftriaxone remains a strong possibility for medication to reduce cocaine relapse in humans.
BACKGROUND:Cocaine use disorder is a significant public health problem and currently no medications are FDA-approved to reduce cocaine relapse. Drug-associated cues are reported to elicit craving and cocaine-seeking in humans. Repeated, non-reinforced presentations of drug-associated cues (cue extinction) have been proposed to reduce the ability of such cues to prompt drug-seeking. In rodent models of cocaine relapse, cue extinction reduces cocaine relapse when such extinction occurs in the same context as cocaine self-administration, which is not akin to the manner in which treatment would occur in humans. Here we sought to determine whether cue extinction outside of the cocaine self-administration context would reduce relapse in the drug context. We also hypothesized that ceftriaxone, an antibiotic consistently shown to attenuate cocaine relapse in rats, would enhance the relapse-preventing effects of cue extinction. METHODS:Rats self-administered intravenous cocaine for 12 days followed by 20-21 days of abstinence. Immediately preceding the relapse test, rats either underwent 6 single daily cue extinction sessions (1 h/day) outside the self-administration context or no extinction with daily handling. Rats also received vehicle or ceftriaxone (200 mg/kg IP) on those six days. RESULTS:Ceftriaxone attenuated cued relapse relative to vehicle-treated rats, but there was no additive effect of cue extinction on cocaine-seeking. Cue extinction alone did not attenuate relapse. CONCLUSIONS: Thus, in agreement with work in humans, when cue extinction is conducted outside the drug-associated context it does not reduce the risk of relapse alone. Ceftriaxone remains a strong possibility for medication to reduce cocaine relapse in humans.
Authors: Lori A Knackstedt; Khaled Moussawi; Ryan Lalumiere; Marek Schwendt; Matthias Klugmann; Peter W Kalivas Journal: J Neurosci Date: 2010-06-09 Impact factor: 6.167
Authors: Kimber L Price; Nathaniel L Baker; Aimee L McRae-Clark; Michael E Saladin; Stacia M Desantis; Elizabeth J Santa Ana; Kathleen T Brady Journal: Psychopharmacology (Berl) Date: 2012-01-11 Impact factor: 4.530
Authors: Heather B Madsen; Isabel C Zbukvic; Sophia J Luikinga; Andrew J Lawrence; Jee Hyun Kim Journal: Neurobiol Learn Mem Date: 2016-09-08 Impact factor: 2.877
Authors: Heather Trantham-Davidson; Ryan T LaLumiere; Kathryn J Reissner; Peter W Kalivas; Lori A Knackstedt Journal: J Neurosci Date: 2012-09-05 Impact factor: 6.167
Authors: Isabel C Zbukvic; Despina E Ganella; Christina J Perry; Heather B Madsen; Christopher R Bye; Andrew J Lawrence; Jee Hyun Kim Journal: Cereb Cortex Date: 2016-03-05 Impact factor: 5.357
Authors: Allison R Bechard; Carly N Logan; Javier Mesa; Yasmin Padovan-Hernandez; Harrison Blount; Virginia L Hodges; Lori A Knackstedt Journal: Addict Biol Date: 2020-06-18 Impact factor: 4.093